Makers Laboratories Ltd

Surpassing its previous peak, Makers Laboratories Ltd touched a fresh 52-week high of Rs 236.55 on 25 Aug 2026, marking a significant milestone in its price journey. This achievement comes amid a backdrop of strong technical momentum, even as the broader market struggles to maintain its footing.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a significant change in price attractiveness. This article analyses the recent valuation changes, compares them with peer averages and historical benchmarks, and assesses the implications for investors amid the company’s strong market performance.

Surging past its previous peak, Makers Laboratories Ltd touched a fresh 52-week high of Rs 187 on 21 Aug 2026, propelled by a sustained six-day rally that has delivered a 20.76% gain in that period alone. This milestone comes amid a broader market environment where the Sensex trades near its own highs, underscoring the stock’s robust momentum within the Pharmaceuticals & Biotechnology sector.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven primarily by its improved price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical levels and peer benchmarks. This re-rating comes amid a backdrop of solid operational metrics and a micro-cap status that offers potential upside for discerning investors.

Makers Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 4 August 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Makers Laboratories Ltd has demonstrated a marked improvement in its financial performance for the quarter ended June 2026, shifting from a positive to a very positive trend. The company’s latest results reveal record-breaking revenue and profitability metrics, signalling a potential turnaround in its micro-cap Pharmaceuticals & Biotechnology segment despite recent market headwinds.

Makers Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving market perceptions amid strong price momentum and improving fundamentals. This article analyses the recent changes in key valuation metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical trends and peer benchmarks to assess the stock’s current price attractiveness.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and recent financial performance. The upgrade, effective from 4 August 2026, is driven by enhanced technical trends, positive quarterly results, and a more favourable valuation compared to peers, despite some lingering concerns over long-term profitability and growth.

Makers Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell by MarketsMOJO as of 27 July 2026. The revision primarily stems from a deterioration in valuation metrics, despite some positive quarterly financial trends and technical signals. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced the change in the company’s Mojo Grade to 47.0, signalling a Sell recommendation.

Makers Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid rising price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock differently against its peers and historical benchmarks.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile and encouraging quarterly financial results. The micro-cap pharmaceutical company’s Mojo Score has risen to 50.0, reflecting a more balanced outlook amid mixed long-term fundamentals and recent operational progress.

Makers Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a reassessment across key parameters including valuation, financial trends, quality, and technical indicators. Despite some positive quarterly results, concerns over long-term profitability and valuation metrics have prompted this change, signalling caution for investors in the pharmaceuticals sector.

Makers Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade. This change reflects evolving market perceptions amid a challenging Pharmaceuticals & Biotechnology sector landscape, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios adjusting relative to historical averages and peer benchmarks.

Makers Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by an improved valuation profile and positive financial trends. The micro-cap pharmaceutical company’s recent performance and comparative metrics have prompted a reassessment of its quality, valuation, financial trend, and technical outlook, culminating in a more favourable stance by analysts.

Makers Laboratories Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade as of late June 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, set against a backdrop of sector-wide valuation trends and company-specific performance metrics.